Assenagon Asset Management S.A. Sells 203,292 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Assenagon Asset Management S.A. cut its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 75.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,231 shares of the company’s stock after selling 203,292 shares during the period. Assenagon Asset Management S.A. owned 0.13% of Cardiff Oncology worth $292,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of CRDF. GSA Capital Partners LLP raised its position in Cardiff Oncology by 432.7% during the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Cardiff Oncology during the 2nd quarter valued at about $185,000. Renaissance Technologies LLC raised its holdings in shares of Cardiff Oncology by 82.9% during the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock valued at $350,000 after buying an additional 71,390 shares in the last quarter. Rhumbline Advisers bought a new stake in Cardiff Oncology in the 2nd quarter worth approximately $102,000. Finally, Barclays PLC boosted its stake in Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after buying an additional 39,542 shares in the last quarter. 16.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Gary W. Pace bought 350,115 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the transaction, the director now directly owns 1,047,876 shares of the company’s stock, valued at approximately $2,724,477.60. The trade was a 50.18 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.80% of the company’s stock.

Cardiff Oncology Trading Down 2.6 %

Shares of NASDAQ:CRDF opened at $3.41 on Friday. The stock has a 50 day moving average of $3.49 and a 200 day moving average of $2.90. The company has a market cap of $174.35 million, a PE ratio of -3.63 and a beta of 1.76. Cardiff Oncology, Inc. has a 12-month low of $1.44 and a 12-month high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The company had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.13 million. Equities research analysts predict that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CRDF. HC Wainwright lowered their target price on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Piper Sandler lifted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.